Ligand Pharmaceuticals Incorporated (LGND) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions.
Is Ligand Pharmaceuticals Incorporated stock overvalued or undervalued in 2026?
Ligand Pharmaceuticals Incorporated (LGND) trades at 144× earnings (P/E). No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Ligand Pharmaceuticals Incorporated
Market cap $6B · 52 weeks $182 – $323 (0 % below the high) · P/E 144× · 2027 expected P/E 26.6× · Dividend none · Next earnings February 25, 2027 · expected EPS $2.87 · Closing price, Oct 30 · accounts published Oct 29.
- Valuation: P/Sales 21.7× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 6 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 1.3 %, fails.
- Market cap / Cash 8.5×, fails.
- Annual cash burn $2.55, passes.
- Total Debt 0.6×, passes.
Against its peers (reference peers) — Ligand Pharmaceuticals Incorporated: P/E 144×; EV/EBITDA 93.2×; ROIC 2.3 %; $6.4B. Exelixis, Inc. (P/E 20.8×; EV/EBITDA 16.1×; ROIC 39.6 %; $17.4B), Incyte Corporation (P/E 64.0×; EV/EBITDA 24.2×; ROIC 6.0 %; $24.5B), Genmab A/S (P/E 45.0×; EV/EBITDA 28.5×; ROIC 9.9 %; $35.1B).
Profitability
| Return on Equity | 5.22% |
| Return on Invested Capital | 2.29% |
| Return on Assets | 2.30% |
| Gross Margin | 107.11% |
| Operating Margin | 11.91% |
| Net Margin | 20.27% |
Financial Health
| Debt / Equity | 1.17 |
| Current Ratio | 13.35 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 5.47 |
Price Performance
| 1 month | +6.53% |
| 3 months | +10.52% |
| Year-to-date | +70.70% |
| 1 year | +68.71% |
| 3 years | +522.95% |
| 5 years | +227.60% |
| 10 years | +467.52% |
Dividend History
| Date | Amount |
|---|---|
| 2010-07-02 | $0.4560 |
| 2007-04-03 | $9.3575 |
Amounts adjusted for stock splits.
Related companies: AMGN · INCY · GMAB · EXEL · BCRX · ABBV · PFE · BMY
Explore sector: Healthcare · Biotechnology
More sections of LGND: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks